Greenland Mines Ltd GRML
๐ Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-04-29 |
| Shares Out. | 150,530,000 |
| Website | greenlandmines.com โ |
| Phone | 13028948922 |
| Employees | 5 |
| Net Income | -$13.9M |
| Total Assets | $59.7M |
| Total Liabilities | $8.3M |
| Equity | $51.5M |
About Greenland Mines Ltd
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Greenland Mines Ltd is a publicly traded company under the ticker symbol GRML on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

